Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24575982 | 0.85 | TSHR (0.71) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL30223375 | 0.84 | CYP2C9 (0.64) | TSHRCYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL12448898 | 0.84 | CYP2C9 (0.59) | TSHRCYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL31362165 | 0.83 | TSHR (0.69) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL11305715 | 0.83 | TSHR (0.69) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL3169688 | 0.83 | TSHR (0.69) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL5653386 | 0.82 | TSHR (0.63) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL5724113 | 0.81 | TSHR (0.72) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4019644 | 0.81 | TSHR (0.57) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL30486705 | 0.81 | TSHR (0.57) | TSHRSMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | claimed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | claimed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | claimed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | claimed |
| US-9192569-B2 | Formulations for infusion of type B lantibiotics | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2603204-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | Novacta Biosystems Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-05-30 | — | — | US | disclosed |
| US-8293919-B2 | Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2012020219-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | disclosed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| US-4405355-A | HERBICIDES | CHEVRON RESEARCH COMPANY (US) | 1983-09-20 | — | — | US | disclosed |
| US-4273572-A | HERBICIDES | CHEVRON RESEARCH COMPANY (US) | 1981-06-16 | — | — | US | disclosed |
| US-4200450-A | HERBICIDES | CHEVRON RESEARCH COMPANY (US) | 1980-04-29 | — | — | US | disclosed |
| US-4111683-A | HERBICIDE | CHEVRON RESEARCH COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4012225-A | Herbicidal 1-alkanoyloxy-haloethyl urea | CHEVRON RESEARCH COMPANY (US) | 1977-03-15 | — | — | US | disclosed |
| US-4007033-A | Herbicidal substituted-haloethyl urea | CHEVRON RESEARCH COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | SLC5A2, SLC5A11, SPTSSB | TSHR 2007/4885CYP2C9 4511/4885CYP2C19 4178/4885 |
| US-20110294723-A1 | Compounds | SLC11A2, SDHA, SDHB | TSHR 4345/4885CYP2C9 102/4885CYP2C19 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.